Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5957952 | 0.89 | KMT2A (0.51) | KMT2AMEN1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5958183 | 0.84 | ALDH1A1 (0.70) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL5957993 | 0.83 | KMT2A (0.81) | KMT2AMEN1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL5899127 | 0.81 | ALDH1A1 (0.74) | KMT2AMEN1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5957748 | 0.80 | HPGD (0.68) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL9523677 | 0.80 | KMT2A (0.60) | KMT2AMEN1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL9827799 | 0.79 | KMT2A (0.59) | KMT2AMEN1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL17335487 | 0.79 | KMT2A (0.70) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL29160842 | 0.78 | TRPV1 (0.68) | KMT2AMEN1MAPTALDH1A1CYP1A2 | |
| SCHEMBL4022887 | 0.78 | KMT2A (0.87) | KMT2AMEN1MAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122065-A1 | Amide compound and method of controlling plant disease with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1577290-A1 | AMIDE COMPOUND AND METHOD OF CONTROLLING PLANT DISEASE WITH THE SAME | Sumitomo Chemical Company, Limited (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122065-A1 | Amide compound and method of controlling plant disease with the same | CBR3, C5, CLN6 | KMT2A 2654/4885MEN1 3030/4885MAPT 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.